1093 — CSPC Pharmaceutical Balance Sheet
0.000.00%
- HK$69.72bn
- HK$63.19bn
- CNY29.01bn
- 90
- 56
- 48
- 74
Annual balance sheet for CSPC Pharmaceutical, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | HKAS | HKAS | HKAS | HKAS | — |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 8,795 | 10,703 | 13,796 | 13,068 | 8,250 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 4,745 | 6,549 | 6,836 | 9,841 | 9,621 |
Total Inventory | |||||
Total Other Current Assets | |||||
Total Current Assets | 15,921 | 20,337 | 23,957 | 26,745 | 21,888 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 8,934 | 9,564 | 10,977 | 11,643 | 12,503 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 30,070 | 34,742 | 41,770 | 46,282 | 44,389 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 6,302 | 7,226 | 8,958 | 10,183 | 9,634 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 7,738 | 8,755 | 11,572 | 13,079 | 12,124 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Other Equity | |||||
Total Equity | 22,332 | 25,987 | 30,198 | 33,203 | 32,265 |
Total Liabilities & Shareholders' Equity | 30,070 | 34,742 | 41,770 | 46,282 | 44,389 |
Total Common Shares Outstanding |